Radiation beads aim to shrink liver tumors in neuroendocrine cancer trial
NCT ID NCT04362436
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a treatment called TheraSphere selective internal radiation therapy (SIRT) in 24 patients with neuroendocrine tumors that had spread to the liver and could not be surgically removed. The treatment involves injecting tiny radioactive beads into the liver's blood supply to deliver radiation directly to tumors. The study measured safety, tumor shrinkage, and how long patients lived without their disease getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TheraSphere (yttrium-90 glass microspheres) for selective internal radiation therapy
- What this could lead to
- If successful, this could offer a new treatment option for patients with inoperable liver metastases from neuroendocrine tumors, potentially improving tumor control and survival.
- What could go wrong
- This is a small, early-phase trial with only 24 participants, so results may not apply broadly. Radiation to the liver carries risks of liver damage, fatigue, and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Imperial College NHS Trust
London, W12 0HS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- A new clue in the fight against colorectal cancer recurrence?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- A new way to read CT scans may predict which liver surgery patients will develop Life-Threatening failure
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?